US-based firm aTyr Pharma has appointed Frederic Chereau as president and chief operating officer to support the advance of its portfolio of medicines for rare diseases.
Chereau has significant experience in the field, working at rare disease specialist Genzyme from 1999 to 2008, eventually becoming president and general manager of the company’s cardiovascular business.
He was later president and CEO of Pervasis Therapeutics, which was acquired by Shire in 2012.
Dr John Mendlein, CEO and executive chairman of aTyr Pharma, said that Chereau’s appointment will guide the company’s “global outreach and strategic partnerships”.